RJFSA
EDIT icon

Raymond James Financial Services Advisors’s Editas Medicine EDIT Stock Holding History

Raymond James Financial Services Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$208K Sell
60,894
-4,203
-6% -$18.3K ﹤0.01% 3167
2024
Q2 		$304K Buy
65,097
+1,218
+2% +$6.87K ﹤0.01% 2861
2024
Q1 		$474K Buy
63,879
+3,709
+6% +$30.8K ﹤0.01% 2560
2023
Q4 		$610K Buy
60,170
+13,574
+29% +$119K ﹤0.01% 2283
2023
Q3 		$363K Sell
46,596
-1,169
-2% -$10K ﹤0.01% 2520
2023
Q2 		$393K Buy
47,765
+2,380
+5% +$20.7K ﹤0.01% 2491
2023
Q1 		$329K Buy
45,385
+5,032
+12% +$44.7K ﹤0.01% 2593
2022
Q4 		$358K Buy
40,353
+60
+0.1% +$659 ﹤0.01% 2470
2022
Q3 		$493K Buy
40,293
+3,265
+9% +$50.9K ﹤0.01% 2255
2022
Q2 		$438K Buy
37,028
+62
+0.2% +$831 ﹤0.01% 2359
2022
Q1 		$703K Sell
36,966
-3,493
-9% -$64.9K ﹤0.01% 2170
2021
Q4 		$1.07M Sell
40,459
-12,453
-24% -$429K ﹤0.01% 1941
2021
Q3 		$2.17M Buy
52,912
+4,470
+9% +$245K ﹤0.01% 1441
2021
Q2 		$2.74M Buy
48,442
+444
+0.9% +$16.4K 0.01% 1304
2021
Q1 		$2.02M Sell
47,998
-12,750
-21% -$726K ﹤0.01% 1403
2020
Q4 		$4.26M Buy
60,748
+12,623
+26% +$519K 0.01% 903
2020
Q3 		$1.35M Buy
48,125
+1,498
+3% +$48.8K ﹤0.01% 1369
2020
Q2 		$1.38M Buy
46,627
+17,224
+59% +$450K ﹤0.01% 1307
2020
Q1 		$583K Buy
29,403
+6,580
+29% +$166K ﹤0.01% 1455
2019
Q4 		$676K Buy
22,823
+4,602
+25% +$115K ﹤0.01% 1780
2019
Q3 		$414K Sell
18,221
-405
-2% -$10K ﹤0.01% 2024
2019
Q2 		$461K Sell
18,626
-4,306
-19% -$103K ﹤0.01% 1981
2019
Q1 		$561K Buy
22,932
+694
+3% +$15.7K ﹤0.01% 1820
2018
Q4 		$506K Sell
22,238
-6,599
-23% -$180K ﹤0.01% 1660
2018
Q3 		$918K Buy
28,837
+6,771
+31% +$219K ﹤0.01% 1518
2018
Q2 		$791K Buy
22,066
+10,556
+92% +$374K ﹤0.01% 1574
2018
Q1 		$382K Buy
11,510
+1,551
+16% +$55.3K ﹤0.01% 1891
2017
Q4 		$306K Buy
+9,959
New +$251K ﹤0.01% 2008

Other funds holding EDIT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's EDIT Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Editas Medicine (EDIT) stake by 6.5% in Q3 2024, selling an estimated $18.3K and leaving 60,894 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #3167.

Raymond James Financial Services Advisors first reported a position in EDIT in Q4 2017 and has held it in 28 quarters since. The position peaked at $4.26M in Q4 2020. 230 funds tracked by Wall St. Rank hold EDIT as of Q3 2024.

  • Raymond James Financial Services Advisors held 60,894 shares of Editas Medicine worth $208K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 4,203 Editas Medicine shares in Q3 2024, an estimated $18.3K.
  • Editas Medicine made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3167 holding.
  • Raymond James Financial Services Advisors first reported a position in Editas Medicine in Q4 2017 and has held it in 28 quarters since.
  • Raymond James Financial Services Advisors's Editas Medicine position peaked at $4.26M in Q4 2020.
  • 230 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.